F2G’s Invasive Mold Medication Obtains Orphan Status

The FDA granted an orphan drug designation to F2G’s potentially first-in-class antifungal drug olorofim for treating infections caused by invasive aspergillosis and lomentospora/scedosporium.

The invasive molds are resistant to antifungal drugs and can be fatal. In November 2019, Olorofim became the first antifungal to receive the FDA’s breakthrough therapy designation.

The company said Olorofim was well tolerated by patients over a median therapy duration of 12 weeks.